First, notable does post a lot of information. Majority of which is industry related to onc & possible outcomes.
That is providing information not pumping as some continually claim.
There are a handful of intersting things discovered , that get posted by others & worth reading.
Then there are the Chrystal clear 2-3 people , who post on this site & others. They offer zero substance, other than to name call, and/ or bash the information provided.
Notablec is neither blowing smoke or pumping. Yes he posts often.
All of his stuff is accurate. Sometimes finding the relevance to Onc/ Pelareorep requires a bit of thought.
Lesding to confusion for Buckt et. al.
Since they can't understand beyond a grade 4 level, they retort by name calling.
Myself? Majority of my posts are observational.
Being thst of the site & Onc/ Pelareorep progress.
Closing on that note.
This coming week will be the start if a new month in quarter #2.
Looking @ ONC investor presentation, They point to many things coming listed as first half of 2024, or 2nd quarter.
items being:
Goblet , cohort #1:advanced PDAC , phase 3 study initiation.
Goblet cohort # 5, newly diagnosed, study initiation.
Goblet cohort #4, anal cancer, enrolment expansion.
All goblet studies are co- therapy with Roche. None of which would even consider advancing , on bad data. Written right in trial parameters. All of which were exceeded.
brwcelet -1, MBc with Pfizer & Merck, overall survival data expected soon**
Response from FDA regarding meeting to discuss acceptance of biomarkers into the MBc phase 3 study.
Onc has indicated MBc phase 3 trial will be detailed
presentation of two clinical updates. At the ASCO cancer conference.
and the AGM.
Those are items that are publicly known.
There is a handful of other on- going studies. Example a bresst cancer trial with Incyte.
bottom line?
There are a lot of expected catalysts/ milestones to be brought into focues , between now & June.
will all of the expected news/ results fall into line time wise?
Could be, however
*** The long awaited MBc overall survival events are based on people's lives. The longer they live the better. Some will incorrectly view the late updates as a mangement failure.
first Onc mangement does not dot get directly involve with those under test,
Second & most important , longer O.S. Is great news for onc/ Pelareorep.
There are a lot of known upcoming events.
Even one getting moved forward will greatly improve the corporate image & obviously the S.P.
The real maximum value will be realized, either a partnership or complete buyout.
My personal comment on that?
Roche would appear to be the most likely business deal opportunity.
Pfize could surprise, if O.S. Numbers prove Pelareorep works long term.
Most existing chemo treatments do not work long term BTW.
some absolutely work with very early detected cancers.
One of the biggest properties of Pelareorep is the ability to prim the imune system and act as a long term preventative of reoccurrence.
Pelareorep only multiplies in cancer cells. Being one of few I.V. Treatments, that does not reqspecial handling & does not need to be I injected into the tumor.
essentially will light up tumours not yet detected.
Enough for today.